Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer

A case is reported in which docetaxel was used to treat a patient with hormone refractory metastatic prostate cancer. The treatment was terminated at the third course of docetaxel following the development of hemorrhagic cystitis. This reaction was unexpected, as it is not a known reaction to doceta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ntekim, A.I., Ajekigbe, A.
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883243/
https://www.ncbi.nlm.nih.gov/pubmed/20567631
_version_ 1782182250896424960
author Ntekim, A.I.
Ajekigbe, A.
author_facet Ntekim, A.I.
Ajekigbe, A.
author_sort Ntekim, A.I.
collection PubMed
description A case is reported in which docetaxel was used to treat a patient with hormone refractory metastatic prostate cancer. The treatment was terminated at the third course of docetaxel following the development of hemorrhagic cystitis. This reaction was unexpected, as it is not a known reaction to docetaxel. Hemorrhagic cystitis has been associated with cyclophosphamide, where the metabolite acrolein has been implicated. The mechanism of this reaction from docetaxel is not yet known.
format Text
id pubmed-2883243
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-28832432010-06-21 Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer Ntekim, A.I. Ajekigbe, A. Clin Med Insights Oncol Case Report A case is reported in which docetaxel was used to treat a patient with hormone refractory metastatic prostate cancer. The treatment was terminated at the third course of docetaxel following the development of hemorrhagic cystitis. This reaction was unexpected, as it is not a known reaction to docetaxel. Hemorrhagic cystitis has been associated with cyclophosphamide, where the metabolite acrolein has been implicated. The mechanism of this reaction from docetaxel is not yet known. Libertas Academica 2010-04-15 /pmc/articles/PMC2883243/ /pubmed/20567631 Text en © 2010 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Case Report
Ntekim, A.I.
Ajekigbe, A.
Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer
title Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer
title_full Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer
title_fullStr Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer
title_full_unstemmed Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer
title_short Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer
title_sort hemorrhagic cystitis in a patient receiving docetaxel for prostate cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883243/
https://www.ncbi.nlm.nih.gov/pubmed/20567631
work_keys_str_mv AT ntekimai hemorrhagiccystitisinapatientreceivingdocetaxelforprostatecancer
AT ajekigbea hemorrhagiccystitisinapatientreceivingdocetaxelforprostatecancer

Ejemplares similares